Clinical application of plasma exchange combined with continuous veno-venous hemofiltration dialysis in children with refractory Kawasaki disease shock syndrome
KANG Xia-Yan, YUAN Yuan-Hong, XU Zhi-Yue, ZHANG Xin-Ping, FAN Jiang-Hua, LUO Hai-Yan, LU Xiu-Lan, XIAO Zheng-Hui
Department of Pediatric Intensive Care Unit, Hunan Children's Hospital, Changsha 410007, China
Abstract Objective To study the role of plasma exchange combined with continuous blood purification in the treatment of refractory Kawasaki disease shock syndrome (KDSS). Methods A total of 35 children with KDSS who were hospitalized in the Department of Pediatric Intensive Care Unit, Hunan Children's Hospital, from January 2019 to August 2022 were included as subjects. According to whether plasma exchange combined with continuous veno-venous hemofiltration dialysis was performed, they were divided into a purification group with 12 patients and a conventional group with 23 patients. The two groups were compared in terms of clinical data, laboratory markers, and prognosis. Results Compared with the conventional group, the purification group had significantly shorter time to recovery from shock and length of hospital stay in the pediatric intensive care unit, as well as a significantly lower number of organs involved during the course of the disease (P<0.05). After treatment, the purification group had significant reductions in the levels of interleukin-6, tumor necrosis factor-α, heparin-binding protein, and brain natriuretic peptide (P<0.05), while the conventional group had significant increases in these indices after treatment (P<0.05). After treatment, the children in the purification group tended to have reductions in stroke volume variation, thoracic fluid content, and systemic vascular resistance and an increase in cardiac output over the time of treatment. Conclusions Plasma exchange combined with continuous veno-venous hemofiltration dialysis for the treatment of KDSS can alleviate inflammation, maintain fluid balance inside and outside blood vessels, and shorten the course of disease, the duration of shock and the length of hospital stay in the pediatric intensive care unit.
KANG Xia-Yan,YUAN Yuan-Hong,XU Zhi-Yue et al. Clinical application of plasma exchange combined with continuous veno-venous hemofiltration dialysis in children with refractory Kawasaki disease shock syndrome[J]. CJCP, 2023, 25(6): 566-571.
KANG Xia-Yan,YUAN Yuan-Hong,XU Zhi-Yue et al. Clinical application of plasma exchange combined with continuous veno-venous hemofiltration dialysis in children with refractory Kawasaki disease shock syndrome[J]. CJCP, 2023, 25(6): 566-571.
Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006[J]. Pediatrics, 2009, 123(3): e401-e405. PMID: 19237439. DOI: 10.1542/peds.2008-2187.
Miao H, Cui Y, Wang F, et al. Continuous hemofiltration plus plasma exchange in patient with Kawasaki disease shock syndrome: a case report and literature review[J]. Ann Clin Lab Sci, 2019, 49(6): 829-834. PMID: 31882435.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184. PMID: 22890468. DOI: 10.1159/000339789.
Li Y, Zheng Q, Zou L, et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition[J]. Pediatr Rheumatol Online J, 2019, 17(1): 1. PMID: 30611297. PMCID: PMC6321686. DOI: 10.1186/s12969-018-0303-4.
Gamez-Gonzalez LB, Moribe-Quintero I, Cisneros-Castolo M, et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease[J]. Pediatr Int, 2018, 60(9): 781-790. PMID: 29888440. DOI: 10.1111/ped.13614.
Fujimaru T, Ito S, Masuda H, et al. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange[J]. Cytokine, 2014, 70(2): 156-160. PMID: 25082649. DOI: 10.1016/j.cyto.2014.07.003.
Sonoda K, Mori M, Hokosaki T, et al. Infliximab plus plasma exchange rescue therapy in Kawasaki disease[J]. J Pediatr, 2014, 164(5): 1128-1132.e1. PMID: 24560183. DOI: 10.1016/j.jpeds.2014.01.020.
Chen LX, Demirjian S, Udani SM, et al. Cytokine clearances in critically ill patients on continuous renal replacement therapy[J]. Blood Purif, 2018, 46(4): 315-322. PMID: 30107381. DOI: 10.1159/000492025.
Park JT, Lee H, Kee YK, et al. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial[J]. Am J Kidney Dis, 2016, 68(4): 599-608. PMID: 27084247. DOI: 10.1053/j.ajkd.2016.02.049.
Quinto BMR, Iizuka IJ, Monte JC, et al. TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment[J]. Cytokine, 2015, 71(2): 255-260. PMID: 25461406. DOI: 10.1016/j.cyto.2014.10.024.
Miklaszewska M, Korohoda P, Zachwieja K, et al. Factors affecting mortality in children requiring continuous renal replacement therapy in pediatric intensive care unit[J]. Adv Clin Exp Med, 2019, 28(5): 615-623. PMID: 30462382. DOI: 10.17219/acem/81051.
Natterer J, Perez MH, Di Bernardo S. Capillary leak leading to shock in Kawasaki disease without myocardial dysfunction[J]. Cardiol Young, 2012, 22(3): 349-352. PMID: 21933461. DOI: 10.1017/S1047951111001314.
Kocak S, Acar T, Ertekin B, et al. The role of heparin-binding protein in the diagnosis of acute mesenteric ischemia[J]. Ulus Travma Acil Cerrahi Derg, 2019, 25(3): 205-212. PMID: 31135943. DOI: 10.5505/tjtes.2018.49139.
Liu L, Shao Y, Zhang Y, et al. Neutrophil-derived heparin binding protein triggers vascular leakage and synergizes with myeloperoxidase at the early stage of severe burns (with video)[J]. Burns Trauma, 2021, 9: tkab030. PMID: 34646891. PMCID: PMC8499692. DOI: 10.1093/burnst/tkab030.
Chew MS, Linder A, Santen S, et al. Increased plasma levels of heparin-binding protein in patients with shock: a prospective, cohort study[J]. Inflamm Res, 2012, 61(4): 375-379. PMID: 22207392. DOI: 10.1007/s00011-011-0422-6.
